Celgene-partnered Antengene preps new China deals as $21M round lands
Just a few months after inking a deal to develop one of Celgene’s experimental cancer drugs for the Chinese market, Antengene has unveiled a $21 million A round to help pay for the work.
Antengene bears some classic marks of a China-based startup. Its CEO is Jay Mei, who held a senior development position with Celgene and spearheaded Revlimid’s approval in China. Celgene, meanwhile, took an equity stake in the company as it passed over Asian rights to its TORC1/2 inhibitor CC-223.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.